TABLE 1.
Baseline characteristics of subjects by cohorts
| SAD cohorts | MAD cohorts | Food effect cohort | |||
|---|---|---|---|---|---|
|
Placebo N = 20 n (%) |
Remibrutinib N = 60 n (%) |
Placebo N = 16 n (%) |
Remibrutinib N = 48 n (%) |
Remibrutinib N = 12 n (%) |
|
| Age in years, median (range) | 46 (22–63) | 51 (18–64) | 46.5 (23–59) | 37 (23–63) | 39 (22–65) |
| Males, n (%) | 15 (75.0) | 44 (73.3) | 12 (75.0) | 47 (97.9) | 9 (75.0) |
| Race, n (%) | |||||
| White | 20 (100) | 58 (96.7) | 16 (100) | 47 (97.9) | 10 (83.3) |
| Asian | – | 2 (3.3) | – | 1 (2.1) | 1 (8.3) |
| Black | – | – | – | – | 1 (8.3) |
| Ethnicity, n (%) | |||||
| Non‐Hispanic or Latino | 19 (95.0) | 59 (98.3) | 16 (100) | 48 (100) | 11 (91.7) |
| Hispanic or Latino | 1 (5.0) | 1 (1.7) | – | – | 1 (8.3) |
| Weight in kg, mean (SD) | 74.0 (11.43) | 77.9 (10.23) | 76.5 (13.08) | 79.9 (10.34) | 82.9 (14.77) |
| Height in cm, mean (SD) | 174.4 (9.91) | 174.8 (8.30) | 177.9 (9.00) | 179.4 (7.79) | 178.0 (7.45) |
| BMI, kg/m2, mean (SD) | 24.2 (2.33) | 25.5 (2.81) | 24.0 (2.36) | 24.8 (2.56) | 26.0 (2.93) |
Abbreviations: BMI, body mass index; MAD, multiple ascending dose; SAD, single ascending doses.